M 061
Alternative Names: LAMANM6P; M-061Latest Information Update: 12 Apr 2023
At a glance
- Originator M6P Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alpha-Mannosidosis
Most Recent Events
- 12 Apr 2023 Discontinued - Preclinical for Alpha-Mannosidosis in USA (unspecified route) (M6P Therapeutics pipeline, April 2023)
- 04 Feb 2021 M 061 is available for licensing as of 04 Feb 2021
- 28 Jan 2021 Recombinant enzyme replacement therapies received rare paediatric disease designations for Lysosomal storage diseases in USA